Among these, theonellasterol G (13) increased the FXR target OSTα and simultaneously PXR target genes SULT2A1 and MDR1, resulting in the first example of FXR modulator and PXR agonist and, thus, a potential lead in the treatment of inflammatory bowel disease [19]. The gene discussed is NR1I2; the disease is inflammatory bowel disease.